- $2.85m
- $1.31m
- $2.00m
Brief: BioAtla Q4 Net Income USD -14.884 Million
Bioatla Inc expected to post a loss of 38 cents a share - Earnings Preview
Bioatla Inc expected to post a loss of 38 cents a share - Earnings Preview
Bioatla Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: BioAtla Q3 Net Income USD -10.586 Million
Bioatla Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Bioatla And Context Therapeutics Announce Exclusive Worldwide License Agreement To Develop And Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Bioatla Inc reports results for the quarter ended in June - Earnings Summary
Brief: BioAtla Q2 Net Income USD -21.072 Million
Bioatla Inc expected to post a loss of 44 cents a share - Earnings Preview
Bioatla Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Bioatla Granted FDA Fast Track Designation For Ozuriftamab Vedotin
Bioatla Inc reports results for the quarter ended in March - Earnings Summary
Brief: BioAtla Q1 Net Income USD -23.234 Million
Bioatla Inc expected to post a loss of 54 cents a share - Earnings Preview
Bioatla Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: BioAtla Q4 Net Income USD -26.925 Million
Bioatla Inc expected to post a loss of 79 cents a share - Earnings Preview
Bioatla Inc expected to post a loss of 79 cents a share - Earnings Preview